



Bangladesh: COVID-19 Emergency Response and Pandemic Preparedness Project (P173757)

SOUTH ASIA | Bangladesh | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 7 | ARCHIVED on 23-Jun-2022 | ISR51889 |

Implementing Agencies: Ministry of Health and Family Welfare, People's Republic of Bangladesh

Key Dates**Key Project Dates**

Bank Approval Date: 03-Apr-2020

Effectiveness Date: 10-Apr-2020

Planned Mid Term Review Date: 30-Jun-2022

Actual Mid-Term Review Date: 15-Jun-2022

Original Closing Date: 31-Dec-2023

Revised Closing Date: 31-Dec-2023

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To support the Government of Bangladesh to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Component 1: Emergency COVID-19 Response:(Cost \$694.60 M)

Component 2: Supporting National and Sub-national, Prevention and Preparedness:(Cost \$4.00 M)

Component 3: Implementation Management and Monitoring and Evaluation:(Cost \$1.40 M)

Component 4: Contingent Emergency Response Component

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Moderately Satisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

The project includes US\$600 million credit from the World Bank and US\$100 million loan from the Asian Infrastructure Investment Bank (AIIB) to support implementation of the government's National Preparedness and Response Plan for COVID-19, including vaccination related activities. The project has been instrumental in supporting the government secure critical supplies during the emergency phase. Now the focus has shifted towards prevention by ensuring vaccination for the people and strengthening health systems to deal with future outbreaks, not only of COVID-19, but any pandemic.

The project has supported the following:

- 68 million doses of vaccines procured and already administered.
- 110 million pieces of auto-disable syringes procured that are being used to administer vaccines.
- 40 ventilators and 200 oxygen concentrators for the Field Hospital at Bangabondhu Sheikh Mujib Medical University (BSMMU) Dhaka;



- 220 ICU beds for the Dhaka North City Corporation (DNCC) COVID hospital;
- 300 ventilators to various hospitals across the country;
- Large quantities of personal protective equipment (PPE), masks, gloves, body bag and COVID-19 testing machines and kits;
- Liquid medical oxygen (LMO) system established at 30 public hospitals in the country. This is a key milestone in health system strengthening as access to oxygen supplies is critical for dealing with COVID-19 as well as other respiratory diseases. These hospitals did not have centralized LMO systems before the project intervention
- National Vaccine Testing Laboratory being set-up at the Directorate General of Drug Administration. This will pave the way for the country to approve vaccines locally, following international protocols.

The World Health Organization (WHO) is leading the technical dialogue with the government in support of COVID-19 preparedness and response activities.

MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of June 15, 2022, 88 MPA-projects had been approved with a total commitment of US\$4.3 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. Six parent projects have been restructured to include vaccine-related procurement. **Total disbursements as of June 15, 2022, amount to US\$3.6 billion or 84% of overall commitments.** This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. **Sixty-seven (67) country projects or 77% of projects approved have reached 70-100% disbursement** (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). **Out of the 67 operations, 48 operations or 72% have disbursed over 90% of commitments. Of these, 30 operations are fully disbursed. There are thirteen (13) operations with closing dates by the end of FY22. Other 10 operations which had closing dates by the end of the FY have extended their closing dates. There are 12 operations with disbursements under 50%. Out of these 12 operations, one has not disbursed, and four have disbursed 30 percent or less.** The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 87 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 8 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-six (86) or 99% of projects approved are disbursing. MNA has the highest percentage of disbursements, followed by SRA, EAP, ECA and LAC, AFE and AFW. Retroactive Financing represents 26% of commitments. **Country teams for operations, which have been under implementation for twelve months or more by June 30, 2022, are preparing Mid-Term Review (MTR) ISRs to inform the Global MPA MTR, which will be prepared early next FY.**

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of mobility restrictions. Bank staff are operating in a hybrid environment with some days at the office and others at home. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements attests to the strong implementation of the Bank' response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach ("Global COVID-19 MPA") was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of



US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. **On June 30, 2021, President Malpass announced the expansion of financing available for COVID-19 vaccine financing to \$20 billion over the next 18 months, adding \$8 billion to the previously announced \$12 billion.** This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG’s overall COVID-19 response.

As of June 15, 2022, the Bank has approved 105 operations (including MPA-V operations) to support vaccine procurement and rollout in 77 countries amounting to \$9.6 billion. The 105 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 105 approved operations: (i) 56 are in Africa – 26 in AFE and 30 in AFW; (ii) 9 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Fifty-three (53) projects are disbursing. **Total disbursements as of June 15, 2022, under these projects amount to US\$3.4 billion or 35% of overall commitments. Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. Sixteen (16) operations have disbursed over 70% of their commitments. Out of the 16, seven have disbursed 90%. Retroactive Financing represents 44% of overall commitments.** Thirteen (13) new operations are under various stages of processing. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Eighty-eight (88) loan/financing agreements have been signed. Also, eighty-six (86) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of mobility restrictions and counterparts and Bank teams are operating in a hybrid environment with some days at the office and some at home. Countries are dealing with new waves of infections, as the Omicron variant continues to spread rapidly among populations.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	☐ Moderate	☐ Moderate	☐ Moderate
Macroeconomic	☐ Substantial	☐ Substantial	☐ Substantial
Sector Strategies and Policies	☐ Moderate	☐ Moderate	☐ Moderate
Technical Design of Project or Program	☐ Substantial	☐ High	☐ Substantial
Institutional Capacity for Implementation and Sustainability	☐ Substantial	☐ Substantial	☐ Moderate
Fiduciary	☐ High	☐ High	☐ High
Environment and Social	☐ Substantial	☐ Substantial	☐ Substantial
Stakeholders	☐ Substantial	☐ High	☐ Substantial
Other	☐ Moderate	☐ Moderate	☐ Moderate
Overall	☐ Substantial	☐ High	☐ Substantial



Results

PDO Indicators by Objectives / Outcomes

Prevent, detect and respond to the threat posed by COVID-19				
▶ Suspected cases of COVID-19 reported and investigated based on national guidelines (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	279,000.00	372,000.00	372,000.00	350,000.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023
▶ Public hospitals with additional capacity for oxygen therapy (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	30.00	30.00	30.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023
▶ Population vaccinated, which is included in the priority population targets as defined in the National Deployment and Vaccination Plan for COVID-19 Vaccines (NDVP) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	46.50	31.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023

Strengthen national systems for public health preparedness				
▶ Public hospitals with isolation capacity (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	30.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023

Intermediate Results Indicators by Components

Component 1: Emergency COVID-19 response				
▶ Laboratories with COVID-19 diagnostic equipment, test kits, reagents, and trained staff per MoHFW guidelines (Number, Custom)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	2.00	2.00	27.00
Date	31-Mar-2020	30-Nov-2021	08-Jun-2022	31-Dec-2023
► National Deployment and Vaccination Plan for COVID-19 Vaccines (NDVP) with input from relevant bodies is updated by the government, as needed (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023
► Vaccination centers with a female vaccinator/attendant present (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023
► Doctors and nurses at district-level facilities trained in IPC per MoHFW guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	80.00
Date	31-Mar-2020	30-Nov-2021	08-Jun-2022	31-Dec-2023

Component 2: Supporting National and Sub-national, Prevention and Preparedness

► Emergency operations center functional with required inputs (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	1.00	1.00	1.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023
► Health care workers who have completed field epidemiology training program (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	150.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023

Component 3: Implementation Management and Monitoring and Evaluation



► Percentage of received grievances that are addressed in the last one month by the existing grievance redressal mechanism (GRM) of DGHS (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	80.00	80.00	60.00
Date	13-Feb-2021	30-Nov-2021	08-Jun-2022	31-Dec-2023

Performance-Based Conditions

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173757	IDA-66050	Effective	USD	100.00	100.00	0.00	42.67	55.96	43%
P173757	IDA-68460	Effective	USD	500.00	500.00	0.00	431.02	34.50	93%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173757	IDA-66050	Effective	03-Apr-2020	10-Apr-2020	10-Apr-2020	31-Dec-2023	31-Dec-2023
P173757	IDA-68460	Effective	18-Mar-2021	11-Apr-2021	15-Apr-2021	31-Dec-2023	31-Dec-2023

Cumulative Disbursements



Restructuring History

Level 2 Approved on 07-May-2021 ,Level 2 Approved on 02-Feb-2022

Related Project(s)

P175837-Additional Financing for and Restructuring of the COVID-19 Emergency Response and Pandemic Preparedness Project